Compounds > 2-(4-amino-5-iodo-7-pyrrolo[2,3-d]pyrimidinyl)-5-(hydroxymethyl)oxolane-3,4-diol
Page last updated: 2024-12-04
2-(4-amino-5-iodo-7-pyrrolo[2,3-d]pyrimidinyl)-5-(hydroxymethyl)oxolane-3,4-diol
The compound you described, 2-(4-amino-5-iodo-7-pyrrolo[2,3-d]pyrimidinyl)-5-(hydroxymethyl)oxolane-3,4-diol, is a **synthetic nucleoside analog**, which means it is a modified version of a naturally occurring building block of DNA and RNA.
Let's break down its structure and importance:
* **Nucleoside:** A nucleoside consists of a nitrogenous base (in this case, 4-amino-5-iodo-7-pyrrolo[2,3-d]pyrimidine) attached to a sugar molecule (here, it's a modified 5-hydroxymethyloxolane, which is similar to the ribose sugar found in RNA).
* **Modifications:** This nucleoside has several modifications that make it interesting for research:
* **4-amino-5-iodo-7-pyrrolo[2,3-d]pyrimidine:** This is a modified purine base that is not found naturally in DNA or RNA. This modification might affect its interactions with DNA or RNA polymerase enzymes, potentially leading to changes in gene expression or replication.
* **5-(hydroxymethyl)oxolane:** This modified sugar molecule might also impact how the nucleoside interacts with other components of cellular machinery.
**Why is it important for research?**
Nucleoside analogs are valuable tools for research because they can:
* **Inhibit DNA and RNA synthesis:** Many nucleoside analogs act as antiviral or anticancer agents by blocking the replication of viruses or the growth of cancer cells.
* **Probe cellular processes:** By incorporating these analogs into DNA or RNA, researchers can study the function of different cellular pathways and processes.
* **Develop new therapeutics:** Researchers continuously investigate new nucleoside analogs with improved efficacy and safety profiles for treating various diseases.
**Specific Potential Applications:**
Given its structure, the compound you mentioned could be investigated for its potential to:
* **Inhibit viral replication:** The modified purine base and sugar could interfere with the replication of viruses, making it a potential antiviral agent.
* **Target specific enzymes:** The compound might selectively inhibit certain enzymes involved in DNA or RNA synthesis, which could be useful for treating specific diseases.
* **Modify gene expression:** The modified nucleoside could potentially be incorporated into DNA or RNA, leading to changes in gene expression or protein production.
**Note:** The exact properties and potential applications of this specific nucleoside analog would need to be studied further in laboratory experiments.
Cross-References
ID Source | ID |
PubMed CID | 1830 |
CHEMBL ID | 63388 |
CHEBI ID | 93817 |
SCHEMBL ID | 2043545 |
Synonyms (41)
Synonym |
BRD-A18497530-001-03-8 |
BRD-A18497530-001-04-6 |
BIO2_000444 |
BIO2_000924 |
BSPBIO_001227 |
BIOMOLKI2_000055 |
IDI1_002199 |
nsc113939 |
nsc-113939 |
BIOMOLKI_000049 |
NCGC00163302-01 |
NCGC00163302-03 |
NCGC00163302-02 |
NCGC00096117-01 |
4-amino-5-iodo-7-(beta-d-ribofuranosyl)pyrrolo[2,3-d]pyrimidine |
KBIO3_001014 |
KBIO2_005703 |
KBIO2_000567 |
KBIOGR_000567 |
KBIOSS_000567 |
KBIO3_001013 |
KBIO2_003135 |
NCGC00163302-04 |
HMS1990M09 |
BMK1-F1 |
HMS1792M09 |
HMS1362M09 |
CHEMBL63388 |
CCG-100653 |
FT-0620520 |
4-amino-5-iodo-7-(b-d-ribofuranosyl)pyrrolo[2,3-d]pyrimidine;7-iodotubercidin |
SCHEMBL2043545 |
7-deaza-7-iodoadenosine |
WHSIXKUPQCKWBY-UHFFFAOYSA-N |
CHEBI:93817 |
AKOS030242162 |
Q27165541 |
2-(4-amino-5-iodo-7-pyrrolo[2,3-d]pyrimidinyl)-5-(hydroxymethyl)oxolane-3,4-diol |
444020-71-7 |
Z2216889315 |
7-iodo-7-deaza-d-guanosine |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Drug Classes (1)
Class | Description |
nucleobase-containing molecular entity | Any compound that has a nucleobase as a part. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (11)
Potency Measurements
Bioassays (6)
Assay ID | Title | Year | Journal | Article |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.20
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 13.20 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.99 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |